
Vaccine makers are developing 26 different RSV vaccines or monoclonal antibodies for all age groups, as they vie for a slice of the rapidly expanding market. Discussions during Thursday’s FDA vaccine advisory committee focused on the “unmet need” for more RSV shots for infants and toddlers and how to move them forward.